TITLE

A Comparison of Itraconazole Versus Fluconazole as Maintenance Therapy for AIDS-Associated Cryptococcal Meningitis

AUTHOR(S)
Saag, Michael S.; Cloud, Gretchen A.; Graybill, J. Richard; Sobel, Jack D.; Tuazon, Carmelita U.; Johnson, Philip C.; Fessel, W. Jeffrey; Moskovitz, Bruce L.; Wiesinger, Barbara; Cosmatos, Dennis; Riser, Laura; Thomas, Carolynn; Hafner, Richard; Dismukes, William E.
PUB. DATE
February 1999
SOURCE
Clinical Infectious Diseases;2/1/1999, Vol. 28 Issue 2, p291
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This study was designed to compare the effectiveness of fluconazole vs. itraconazole as mainte-nance therapy for AIDS-associated cryptococcal meningitis. HIV-infected patients who had been successfully treated (achieved negative culture of CSF) for a first episode of cryptococcal meningitis were randomized to receive fluconazole or itraconazole, both at 200 mg/d, for 12 months. The study was stopped prematurely on the recommendation of an independent Data Safety and Monitoring Board. At the time, 13 (23%) of 57 itraconazole recipients had experienced culture-positive relapse, compared with 2 relapses (4%) noted among 51 fluconazole recipients (P = .006). The factor best associated with relapse was the patient having not received flucytosine during the initial 2 weeks of primary treatment for cryptococcal disease (relative risk = 5.88; 95% confidence interval, 1.27-27.14; P = .04). Fluconazole remains the treatment of choice for maintenance therapy for AIDS-associated cryptococcal disease. Flucytosine may contribute to the prevention of relapse if used during the first 2 weeks of primary therapy.
ACCESSION #
6235456

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics